Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell …
Over the last 12 months, insiders at Rocket Pharmaceuticals, Inc. have bought $0 and sold $12.64M worth of Rocket Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rocket Pharmaceuticals, Inc. have bought $24.07M and sold $19.45M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,355,932 shares for transaction amount of $20M was made by WONG RODERICK (director) on 2022‑10‑06.
2024-11-21 | Sale | CEO | 11,091 0.0122% | $13.05 | $144,782 | +5.90% | ||
2024-11-21 | Sale | See Remarks | 4,588 0.005% | $13.05 | $59,892 | +5.90% | ||
2024-11-21 | Sale | General Counsel | 1,175 0.0013% | $13.05 | $15,338 | +5.90% | ||
2024-11-21 | Sale | See Remarks | 1,224 0.0013% | $13.05 | $15,978 | +5.90% | ||
2024-10-31 | Sale | See Remarks | 3,080 0.0034% | $16.63 | $51,205 | -16.04% | ||
2024-10-31 | Sale | See Remarks | 917 0.001% | $16.63 | $15,245 | -16.04% | ||
2024-08-16 | Sale | CEO | 9,650 0.0105% | $18.50 | $178,564 | 0.00% | ||
2024-08-16 | Sale | See Remarks | 3,989 0.0043% | $18.50 | $73,812 | 0.00% | ||
2024-08-16 | Sale | General Counsel | 1,027 0.0011% | $18.50 | $19,004 | 0.00% | ||
2024-08-16 | Sale | See Remarks | 1,064 0.0012% | $18.50 | $19,688 | 0.00% | ||
2024-07-22 | Sale | See Remarks | 812 0.0009% | $23.02 | $18,688 | -27.26% | ||
2024-07-08 | Sale | See Remarks | 3,026 0.0032% | $20.39 | $61,715 | 0.00% | ||
2024-05-16 | Sale | CEO | 9,790 0.0108% | $23.35 | $228,597 | -19.30% | ||
2024-05-16 | Sale | See Remarks | 4,046 0.0045% | $23.35 | $94,474 | -19.30% | ||
2024-05-16 | Sale | General Counsel | 1,048 0.0012% | $23.35 | $24,471 | -19.30% | ||
2024-05-16 | Sale | See Remarks | 1,079 0.0012% | $23.35 | $25,195 | -19.30% | ||
2024-04-22 | Sale | See Remarks | 833 0.0009% | $22.87 | $19,051 | -18.52% | ||
2024-04-15 | Sale | director | 10,000 0.0111% | $24.05 | $240,520 | -18.16% | ||
2024-04-12 | Sale | director | 70,000 0.0779% | $24.36 | $1.71M | -18.60% | ||
2024-04-08 | Sale | See Remarks | 12,532 0.014% | $24.64 | $308,763 | -18.53% |
Shah Gaurav | CEO | 707328 0.6627% | $11.56 | 1 | 10 | <0.0001% |
Patel Kinnari | See Remarks | 392395 0.3676% | $11.56 | 2 | 7 | +84.02% |
SOUTHWELL DAVID P | director | 114784 0.1075% | $11.56 | 1 | 5 | +4.41% |
WONG RODERICK | director | 17628567 16.5159% | $11.56 | 1 | 0 | +5.69% |
RTW INVESTMENTS, LP | 15460119 14.4843% | $11.56 | 3 | 1 | <0.0001% |
RTW Investments, LP | $476.51M | 19.48 | 17.69M | 0% | +$0 | 7.14 | |
Wellington Management Company | $246.67M | 10.09 | 9.16M | +11.69% | +$25.82M | 0.04 | |
BlackRock | $159.75M | 6.53 | 5.93M | <0.01% | -$7,219.92 | <0.01 | |
The Vanguard Group | $144.69M | 5.92 | 5.37M | -1.41% | -$2.07M | <0.01 | |
State Street | $112.96M | 4.62 | 4.19M | +29.76% | +$25.91M | 0.01 |